Biogen (BIIB), UCB Report Topline Results from Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Tweet Send to a Friend
Today UCB (UCB) and Biogen Inc. (NASDAQ: BIIB) announced top-line results from a Phase 2b study evaluating the safety and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
